Kodiak Sciences (NASDAQ:KOD) Stock Bumped Up to Sell by Wall Street Zen

Key Points

• Wall Street Zen upgraded Kodiak Sciences from “strong sell” to “sell,” but broader analyst sentiment remains positive, with six Buy ratings, one Hold and one Sell. The consensus rating is “Moderate Buy,” with an average price target of $100.43.
• Kodiak shares opened at $94.45 after a sharp rally, trading near their 12-month high of $104.00. Despite the momentum, the company remains unprofitable and recently reported an adjusted loss of $1.05 per share, below analysts’ expectations.
• Insider buying has been significant: insiders purchased roughly 1.94 million shares worth $157 million over the past 90 days, and insiders collectively own 44.4% of the company. Kodiak is also supported by potential Phase 3 success for its lead retinal-disease treatment, though regulatory and execution risks remain.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a research note issued to investors on Sunday, Wall Street Zen reports.

A number of other equities analysts have also commented on KOD. JPMorgan Chase & Co. raised their target price on shares of Kodiak Sciences from $56.00 to $66.00 and gave the stock an "overweight" rating in a research report on Monday, August 3rd. UBS Group increased their price objective on Kodiak Sciences from $80.00 to $120.00 and gave the stock a "buy" rating in a research note on Monday, September 28th. HC Wainwright raised their price objective on Kodiak Sciences from $58.00 to $96.00 and gave the stock a "buy" rating in a report on Monday, September 28th. Jefferies Financial Group reaffirmed a "buy" rating and set a $112.00 target price on shares of Kodiak Sciences in a research report on Monday, September 28th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and issued a $103.00 target price on shares of Kodiak Sciences in a report on Wednesday. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $100.43.

Kodiak Sciences Trading Down 4.1%

Kodiak Sciences stock opened at $94.45 on Friday. Kodiak Sciences has a 12-month low of $10.94 and a 12-month high of $104.00. The firm has a 50 day moving average of $43.53 and a 200 day moving average of $39.69. The firm has a market capitalization of $5.94 billion, a price-to-earnings ratio of -22.54 and a beta of 2.03.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.96) by ($0.09). On average, analysts predict that Kodiak Sciences will post -3.97 EPS for the current year.

Insider Transactions at Kodiak Sciences

In other news, Director Bros. Advisors Lp Baker bought 807,840 shares of Kodiak Sciences stock in a transaction on Monday, September 28th. The stock was acquired at an average cost of $72.57 per share, for a total transaction of $58,624,948.80. Following the completion of the acquisition, the director owned 19,121,134 shares of the company's stock, valued at $1,387,620,694.38. This trade represents a 4.41% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders bought a total of 1,941,755 shares of company stock valued at $156,986,026 in the last 90 days. 44.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of KOD. Arizona State Retirement System boosted its stake in Kodiak Sciences by 6.9% in the second quarter. Arizona State Retirement System now owns 8,533 shares of the company's stock valued at $332,000 after acquiring an additional 554 shares in the last quarter. Westfuller Advisors LLC purchased a new stake in shares of Kodiak Sciences during the 1st quarter valued at $26,000. V Square Quantitative Management LLC purchased a new stake in shares of Kodiak Sciences during the 1st quarter valued at $26,000. EverSource Wealth Advisors LLC boosted its position in shares of Kodiak Sciences by 94.5% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,927 shares of the company's stock worth $73,000 after purchasing an additional 936 shares in the last quarter. Finally, KBC Group NV acquired a new stake in shares of Kodiak Sciences in the 1st quarter worth $39,000. Hedge funds and other institutional investors own 89.06% of the company's stock.

Key Kodiak Sciences News

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Positive Phase 3 results remain the primary catalyst. Kodiak’s Zenkuda/KSI-501 reportedly met key goals in the DAYBREAK trial for wet age-related macular degeneration, outperforming or matching Eylea on important endpoints. The results support plans to pursue a biologics license application and strengthen the company’s potential position in the large retinal-disease market. Kodiak Sciences more than doubles on eye disease trial results
• Positive Sentiment: Analyst price targets have moved higher. Kodiak’s consensus target reportedly increased 65.16% to $117.50. Jefferies maintains a Buy rating with a $112 target, while HC Wainwright raised its target to $96 and lifted longer-term earnings estimates based on the trial opportunity. Kodiak Sciences consensus price target increased
• Positive Sentiment: Insider buying provides an additional confidence signal. Director Bros. Advisors LP Baker purchased 33,726 shares at about $85.05, following several larger purchases totaling roughly 1.94 million shares in late September. Kodiak Sciences insider purchase
• Neutral Sentiment: Expectations for future earnings are being reset. Brokers are forecasting continued losses in the near term, but the potential commercial impact of Zenkuda has led to substantially improved FY2027-and-beyond estimates. Kodiak Sciences FY2027 earnings expectations
• Negative Sentiment: The stock’s rapid advance raises near-term correction risk. Shares have climbed from roughly $37 to above $100 in about a month and have delivered a gain of more than 500% over the past year. Such momentum can encourage profit-taking, while Kodiak remains an unprofitable biotechnology company with execution, regulatory and financing risks. Kodiak Sciences comeback and dealmaking

About Kodiak Sciences

Kodiak Sciences Inc NASDAQ: KOD is a clinical-stage biopharmaceutical company focused on developing medicines for serious retinal diseases. The company's research is centered on its Antibody Biopolymer Conjugate (ABC) platform, which is designed to combine antibody-based therapies with biopolymer technology to potentially extend the duration of treatment in the eye.

Kodiak's lead programs have focused on ophthalmic diseases involving abnormal blood-vessel growth or leakage, including wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.